baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

VIATRIS INC/ US92556V1061 /

5/22/2024 5:06:27 PM	Chg. -	Volume	Bid5:40:00 PM	Ask5:40:00 PM	Market Capitalization	Dividend Y.	P/E Ratio
10.140EUR	-	1 Turnover: 10.175	-Bid Size: -	-Ask Size: -	11.64 bill.EUR	-	-

GlobeNewswire 5/10 Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update

GlobeNewswire 5/6 Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting

GlobeNewswire 5/3 Ocuphire Pharma to Present at the Aegis Virtual Conference

GlobeNewswire 5/1 NeurologyLive® and CMSC Announce the 3rd Annual Class of Inductees

GlobeNewswire 4/22 Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting

GlobeNewswire 4/11 First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS...

GlobeNewswire 4/1 Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) b...

GlobeNewswire 3/20 Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Boar...

GlobeNewswire 3/8 Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corpo...

TeleTrader 2/28 US closes lower after GDP data, ahead of earnings

GlobeNewswire 2/28 Idorsia and Viatris enter into a significant global research and development collaboration

GlobeNewswire 2/23 Ocuphire Pharma to Present in the BIO CEO & Investor Conference

GlobeNewswire 2/15 Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 2/14 ACTG Announces Launch of Clinical Trial Evaluating Drug-Drug Interaction in Shortened Tuberculosis R...

GlobeNewswire 2/14 Ocuphire Pharma Strengthens Leadership Team with Key Appointments

GlobeNewswire 2/5 Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degener...

GlobeNewswire 2/2 Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

GlobeNewswire 1/24 Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 1/4 Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of...

GlobeNewswire 1/2 VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stoc...

GlobeNewswire 11/30/2023 Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII

GlobeNewswire 11/30/2023 Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries ...

GlobeNewswire 11/27/2023 Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 11/27/2023 Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

GlobeNewswire 11/13/2023 Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update

VIATRIS INC/ US92556V1061 /

If you wish to receive reply to your feedback, please provide your email address.